ArticleMikrochimica acta2026
Portable colorimetric device for low-density lipoproteins detection using aptamer-enhanced NiMnFe layered double hydroxide nanozyme.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
A portable colorimetric platform was developed for rapid, selective, and sensitive detection of cholesterol-enriched low-density lipoprotein (LDL-C) in plasma by exploiting the aptamer-enhanced catalytic activity of NiMnFe layered double hydroxides (NiMnFe-LDHs). Unlike conventional enzymatic colorimetric assays and ELISA, which are costly, time-consuming, and reliant on sophisticated instrumentation, this system enables direct image acquisition and automated analysis using a single-board computer, thereby reducing assay time, operational complexity, and user dependence. Functionalization of NiMnFe-LDHs with an LDL-specific aptamer improves nanomaterial dispersion through electrostatic repulsion, increasing exposure of catalytic active sites and enhancing hydroxyl radical (•OH) generation. In addition, π–π interactions and hydrogen bonding between the aptamer and 3,3′,5,5′-tetramethylbenzidine (TMB) improve substrate affinity, further strengthening the peroxidase-like activity of the NiMnFe-LDHs@aptamer system. Upon LDL-C binding, formation of an LDL-C/aptamer corona partially blocks the LDH surface, limiting access of TMB and H2O2 to catalytic sites. This suppresses •OH generation and TMB oxidation, resulting in a concentration-dependent decrease in colorimetric signal. The portable device achieved a linear detection range of 0.05–1.25 mg dL⁻¹ with a detection limit of 0.04 mg dL⁻¹. Although compatible with 96-well plates, the system’s key advantage lies in its integrated imaging and processing workflow, enabling scalable, high-throughput, and decentralized LDL-C diagnostics with potential extension to other biomarkers.
Indexed as
Identifiers
41951981What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.